IE
NXTC icon

Israel Englander’s NextCure NXTC Stock Holding History

Israel Englander’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$141K Buy
+88,112
New +$651K ﹤0.01% 5411
2026
Q1 		– Sell
-13,033
Closed -$185K – 6172
2025
Q4 		$185K Buy
+13,033
New +$135K ﹤0.01% 5491
2025
Q2 		– Sell
-1,023
Closed -$5.89K – 6196
2025
Q1 		$5.89K Sell
1,023
-2,520
-71% -$22.2K ﹤0.01% 5708
2024
Q4 		$32.8K Sell
3,543
-2,467
-41% -$36.3K ﹤0.01% 5654
2024
Q3 		$98.8K Sell
6,010
-32,185
-84% -$592K ﹤0.01% 5590
2024
Q2 		$729K Sell
38,195
-56,312
-60% -$1.1M ﹤0.01% 4341
2024
Q1 		$2.53M Sell
94,507
-525
-0.6% -$9.04K ﹤0.01% 3516
2023
Q4 		$1.3M Sell
95,032
-23,514
-20% -$341K ﹤0.01% 3950
2023
Q3 		$1.84M Buy
118,546
+1,125
+1% +$21.5K ﹤0.01% 3635
2023
Q2 		$2.54M Sell
117,421
-3,747
-3% -$73.8K ﹤0.01% 3268
2023
Q1 		$2.15M Buy
121,168
+9,752
+9% +$188K ﹤0.01% 3375
2022
Q4 		$1.89M Buy
111,416
+10,124
+10% +$233K ﹤0.01% 3623
2022
Q3 		$3.34M Buy
101,292
+8,426
+9% +$429K ﹤0.01% 3274
2022
Q2 		$5.24M Buy
92,866
+8,424
+10% +$440K ﹤0.01% 2760
2022
Q1 		$4.92M Buy
84,442
+443
+0.5% +$27.7K ﹤0.01% 2956
2021
Q4 		$6.05M Buy
83,999
+35,155
+72% +$2.94M ﹤0.01% 2707
2021
Q3 		$3.95M Buy
48,844
+15,234
+45% +$1.34M ﹤0.01% 3141
2021
Q2 		$3.24M Buy
33,610
+26,102
+348% +$2.67M ﹤0.01% 3338
2021
Q1 		$902K Buy
7,508
+196
+3% +$28.4K ﹤0.01% 4320
2020
Q4 		$956K Sell
7,312
-33,909
-82% -$4.38M ﹤0.01% 3772
2020
Q3 		$4.35K Buy
41,221
+29,997
+267% +$3.69M 0.01% 1969
2020
Q2 		$2.89M Buy
11,224
+5,914
+111% +$2.25M ﹤0.01% 2252
2020
Q1 		$2.36M Buy
5,310
+939
+21% +$501K 0.01% 1895
2019
Q4 		$2.96M Buy
+4,371
New +$2.19M ﹤0.01% 2349
2019
Q3 		– Sell
-2,511
Closed -$451K – 4444
2019
Q2 		$451K Buy
+2,511
New +$522K ﹤0.01% 3303

Other funds holding NXTC

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
Verdad Advisers Boston, Massachusetts $104M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Israel Englander's NXTC Position: Q2 2026 in Review

Israel Englander opened a new position in NextCure (NXTC) in Q2 2026: 88,112 shares worth $141K. The stake represents ﹤0.01% of the portfolio and ranks #5411 among its holdings. This is a return to the name: Israel Englander previously reported a position in NXTC as recently as Q4 2025.

Israel Englander first reported a position in NXTC in Q2 2019 and has held it in 25 quarters since. The position peaked at $6.05M in Q4 2021. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

  • Israel Englander held 88,112 shares of NextCure worth $141K as of Q2 2026.
  • NextCure was a new Israel Englander position in Q2 2026.
  • NextCure made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5411 holding.
  • Israel Englander first reported a position in NextCure in Q2 2019 and has held it in 25 quarters since.
  • Israel Englander's NextCure position peaked at $6.05M in Q4 2021.
  • 30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.